Key result
Fenoldopam demonstrated alpha-adrenoceptor antagonist activity in isolated rabbit and dog arteries, competing with alpha-phenoxybenzamine for the same receptor site.
Fenoldopam, a selective DA1 agonist, also possesses alpha-adrenoceptor antagonist activity in isolated vascular preparations.
Answers are grounded in this paper and cite their sources.
Suggests broader vascular effects of fenoldopam beyond DA1 agonism; leaves open applicability to human cardiovascular therapy.
The alpha-adrenoceptor blocking activity of fenoldopam (SK&F 82526), a selective dopamine vascular receptor (DA1) agonist, was evaluated in isolated segmental preparations of rabbit aorta, dog mesenteric and rabbit splenic arteries. Fenoldopam, in concentrations ranging from 10(-6) to 10(-4) M, produced parallel, dextral shifts of concentration-contractile response curves to noradrenaline. Slopes of the Schild regression lines were not significantly different from unity in the three vessels. pA2 values for fenoldopam in the rabbit aorta, dog mesenteric and rabbit splenic arteries were 5.48 +/- 0.08, 5.78 +/- 0.05, and 5.20 +/- 0.05, respectively. In experiments where the drug was added to the bathing medium before exposing the vascular segments to the irreversible alpha-adrenoceptor antagonist, phenoxybenzamine, fenoldopam provided nearly complete protection against alpha-adrenoceptor blockade. These results demonstrate that fenoldopam possesses alpha-adrenoceptor antagonist activity and competes with alpha-phenoxybenzamine, for occupancy at the same receptor site.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (1986) studied this question. Fenoldopam (SK&F 82526) vs. Noradrenaline / Phenoxybenzamine was evaluated on alpha-adrenoceptor blocking activity (pA2 values). Fenoldopam demonstrated alpha-adrenoceptor antagonist activity in isolated rabbit and dog arteries, competing with alpha-phenoxybenzamine for the same receptor site.
Synapse has enriched 10 related papers. Consider them for comparative context: